This selectivity is related to higher expression of TRAIL receptors DR4 and DR5 (death receptor 4 and 5) on tumor than on normal cells, but involves multiple additional mechanisms, such as cFLIP- and XIAP-dependent inhibition of apoptosis or overexpression of TRAIL decoy receptors in normal cells (4, 5). The gene discussed is TNFRSF10A; the disease is neoplasm.